Migraine News and Research

Latest Migraine News and Research

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Inc. today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner at the MIP Awards Luncheon on December 10, 2010.

13 Dec 2010

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BioDelivery Sciences International, Inc. today announced the enrollment and dosing of the first patient in its Phase 3 clinical program evaluating the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

9 Dec 2010

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark.

7 Dec 2010

Restless legs syndrome during pregnancy may reappear later on

Women with transient restless legs syndrome (RLS) during pregnancy appear to be at a higher risk of developing a chronic form of RLS later in life or have the same symptoms during future pregnancies, according to new research published in the December 7, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology. RLS is a sleep-related motor disorder that causes an unpleasant feeling in the legs. The condition generally worsens during rest at night and improves with movement. Symptoms tend to progress with age.

7 Dec 2010

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Zogenix, Inc. and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-Free Delivery System. Denmark is the first country in Europe to grant marketing authorization for SUMAVEL DosePro for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.

2 Dec 2010

Physicians prescribe less pain medications for individuals evading the police

If you should find yourself running from the police, watch your step. If you fall and break an ankle, chances are you'll receive less pain medication when they take you to the ER for treatment.

1 Dec 2010

Migraine headache with aura increases risk of stroke among women: Research

Women with a history of migraine headache with aura (transient neurological symptoms, mostly visual impairments) are at increased risk of stroke. However, according to new research reported in Circulation: Journal of the American Heart Association stroke events in women with migraine with aura are more likely to have mild or no disability compared to those without migraine.

1 Dec 2010

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

New data on UCB's anti-epileptic drug (AED) Vimpat (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7, 2010. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam.

1 Dec 2010

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

30 Nov 2010

New tool helps doctors gauge how well they care for people with Parkinson's disease

The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

30 Nov 2010

Breastfeeding while remaining on epilepsy medications may not affect child's IQ

There's good news for women with epilepsy. Breastfeeding your baby while taking your seizure medication may have no harmful effect on your child's IQ later on, according to a study published in the November 24, 2010, online issue of Neurology-, the medical journal of the American Academy of Neurology.

25 Nov 2010

American Board Diplomat joins Ascendant Neuro for treating pain management

Ascendant Neuro is pleased to announce the addition of Jack A. Chapman, M.D., a nationally recognized pain management specialist, who will work to further advance the group's minimally invasive pain treatment techniques through the innovative use of neurostimulators and other conservative treatments.

25 Nov 2010

Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference

Winston Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

22 Nov 2010

Handwriting problems in autistic children likely to continue into teenage years: Study

A new study suggests that the handwriting problems that affect children with autism are likely to continue into their teenage years.

16 Nov 2010

Study suggests mid-life cholesterol level may not linked to later development of Alzheimer's disease

Contrary to earlier research, a new, long-term study suggests that cholesterol level in mid-life may not be linked to later development of Alzheimer's disease, according to a study published in the November 10, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology. However, the results suggest that large decreases in cholesterol levels in old age could be a better predictor of developing the memory-robbing disease.

11 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

8 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Allergan third quarter diluted loss per share increases to $2.21

Allergan, Inc. today announced operating results for the quarter ended September 30, 2010. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2010 to stockholders of record on November 10, 2010.

1 Nov 2010

Migraine News and Research

Latest Migraine News and Research

Majority of brain tumor patients use alternative therapies

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Restless legs syndrome during pregnancy may reappear later on

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Physicians prescribe less pain medications for individuals evading the police

Migraine headache with aura increases risk of stroke among women: Research

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

Zogenix completes enrollment in ZX002 Phase 3 study for moderate to severe pain

New tool helps doctors gauge how well they care for people with Parkinson's disease

Breastfeeding while remaining on epilepsy medications may not affect child's IQ

American Board Diplomat joins Ascendant Neuro for treating pain management

Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference

Handwriting problems in autistic children likely to continue into teenage years: Study

Study suggests mid-life cholesterol level may not linked to later development of Alzheimer's disease

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Allergan third quarter diluted loss per share increases to $2.21

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Migraine News and Research

Latest Migraine News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in